Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth

Rhea-AI Summary

Fifty 1 Labs (OTC: FITY) announced a strategic shift to become a peptide-focused biotechnology and telehealth company centered on peptide science, musculoskeletal health, recovery, and evidence-based product innovation. The evolving strategy combines peptide R&D, AI-enabled discovery workflows, and a planned U.S. telehealth peptide services platform.

Planned R&D may cover candidates such as BPC-157, TB-500, MOTS-c, sermorelin, novel analogues, and delivery concepts, with activities spanning in silico design, pathway mapping, formulation assessment, preclinical planning, and clinical-protocol development for potential Phase I–III studies. In parallel, the company aims to build a telehealth model enabling digital intake, clinical evaluation, and, where permitted, prescriptions for individualized peptide therapies dispensed by compounding pharmacies, under licensed clinical oversight and applicable U.S. regulatory and professional requirements.

The company emphasizes that all peptide candidates and services remain investigational and that there is no assurance any program, telehealth service, partnership, acquisition, financing, or commercialization effort will succeed, generate revenue, or achieve profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services

VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation.

The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform. Fifty 1 Labs intends to pursue peptide products and programs that may include BPC-157, TB-500, MOTS-c, sermorelin, novel analogues, delivery concepts, and peptide-related technologies. The Company's proposed R&D activities are expected to include in silico candidate generation, pathway mapping, formulation assessment, preclinical planning, and clinical-protocol development for future Phase I through Phase III studies where appropriate.

In parallel, Fifty 1 Labs intends to develop a telehealth services model through which eligible patients may complete digital intake, receive virtual or in-person clinical evaluation, and, where clinically indicated and legally permitted, receive prescriptions for individualized peptide-based therapies dispensed by qualified compounding pharmacies. This service line is expected to be structured around licensed clinical oversight, patient-support workflows, laboratory and monitoring pathways, and compliance with applicable healthcare, telemedicine, pharmacy, compounding, advertising, and professional-practice requirements.

"Fifty 1 Labs is being built around a simple but ambitious premise: peptide innovation should be scientifically credible, clinically responsible, and commercially executable," said Joel J. Gagnier, Ph.D., MSc, N.D., Chief Executive Officer of Fifty 1 Labs. "Our strategy is not limited to one product or one channel. We are building a platform that can support discovery, evidence generation, clinical development, partnerships, and direct-to-patient services under an appropriate regulatory posture."

The Company cautions that its peptide research candidates remain investigational unless and until applicable regulatory authorization or approval is obtained. There can be no assurance that any peptide candidate, telehealth service, acquisition, partnership, financing, or commercialization initiative will be successfully completed, generate revenue, or achieve profitability.

About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services. The Company's strategy includes R&D, partnerships, potential acquisitions, clinical-development planning, and commercialization pathways where legally permissible.

Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1labs.com

Forward-Looking Statements
Safe Harbor Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as "may," "will," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company's Disclosure Statements. The company undertakes no obligation to update these statements.

SOURCE: Fifty 1 Labs, Inc.

View the original press release on ACCESS Newswire

FAQ

What strategic shift did Fifty 1 Labs (FITY) announce on July 10, 2026?

Fifty 1 Labs announced it is positioning itself as a peptide biotechnology and telehealth company. According to Fifty 1 Labs, its strategy combines peptide R&D, AI-enabled discovery, and a planned U.S.-focused telehealth peptide services platform centered on musculoskeletal health, recovery, and evidence-driven product innovation.

What peptide programs is Fifty 1 Labs (FITY) planning to explore?

Fifty 1 Labs plans to explore peptide products and programs that may include BPC-157, TB-500, MOTS-c, sermorelin, novel analogues, delivery concepts, and peptide-related technologies. According to Fifty 1 Labs, these candidates remain investigational until applicable regulatory authorization or approval is obtained for specific uses.

How will the planned telehealth peptide services of Fifty 1 Labs (FITY) work?

Fifty 1 Labs plans a U.S.-focused telehealth model where eligible patients complete digital intake, then receive virtual or in-person evaluation. According to Fifty 1 Labs, when clinically indicated and legally permitted, clinicians may prescribe individualized peptide-based therapies dispensed by qualified compounding pharmacies under licensed clinical oversight and compliance frameworks.

Does Fifty 1 Labs (FITY) have approved peptide therapies or guaranteed revenue from its new strategy?

Fifty 1 Labs states its peptide research candidates and proposed services remain investigational and unapproved. According to Fifty 1 Labs, there can be no assurance any peptide candidate, telehealth service, acquisition, partnership, financing, or commercialization initiative will be completed, generate revenue, or achieve profitability.

What role will AI-enabled discovery play in Fifty 1 Labs (FITY) peptide platform?

AI-enabled discovery will support peptide candidate generation and development workflows at Fifty 1 Labs. According to Fifty 1 Labs, proposed R&D includes in silico candidate generation, pathway mapping, formulation assessment, preclinical planning, and clinical-protocol development to potentially support future Phase I through Phase III studies where appropriate.

What regulatory and compliance focus does Fifty 1 Labs (FITY) highlight for its telehealth services?

Fifty 1 Labs plans its telehealth services around licensed clinical oversight and robust compliance. According to Fifty 1 Labs, operations are expected to align with applicable healthcare, telemedicine, pharmacy, compounding, advertising, and professional-practice requirements, alongside laboratory and monitoring pathways and patient-support workflows in the United States.